Table 2 Venous thromboembolism prophylaxis administration practices in the intensive care unit

VTE prophylaxis administered

199 (99%)

101 (99%)

98 (100%)

0.99

 Pharmacologic prophylaxis administered

98 (49%)

55 (54%)

43 (44%)

0.16

 Mechanical prophylaxis administered

197 (98%)

100 (98%)

97 (99%)

0.99

 Mechanical only

101 (51%)

46 (45%)

55 (56%)

0.12

 Pharmacologic only

2 (1%)

1 (1%)

1 (1%)

0.99

 Both

96 (48%)

54 (53%)

42 (43%)

0.15

Pharmacologic prophylaxis administered

< 0.01

 Enoxaparin only

71 (73%)

52 (95%)

19 (45%)

 Heparin only

17 (18%)

3 (5%)

14 (33%)

 Apixaban only

1 (1%)

0 (0%)

1 (2%)

 Heparin, followed by enoxaparin

4 (4%)

0 (0%)

4 (10%)

 Enoxaparin, followed by heparin

2 (2%)

0 (0%)

2 (5%)

 Enoxaparin, followed by apixaban

1 (1%)

0 (0%)

1 (2%)

 Simultaneous heparin and enoxaparin

1 (1%)

0 (0%)

1 (2%)

Interruption of pharmacologic prophylaxis after initiation

10 (10%)

5 (9%)

5 (12%)

0.74

 Interruption of enoxaparin

8 (10%)

5 (10%)

3 (11%)

0.99

 Interruption of heparin

2 (8%)

0 (0%)

2 (9%)

0.99

Time between admission and pharmacologic prophylaxis initiation (hours), median (IQR)

23 (8–76)

53 (15–107)

10 (2–25)

< 0.01

 Admission to enoxaparin initiation (hours), median (IQR)

30 (14–77)

53 (15–95)

17 (4–25)

< 0.01

 Admission to heparin initiation (hours), median (IQR)

7 (0–29)

131 (17–188)

4 (0–21)

0.03

 Admission to apixaban initiation (hours), median (IQR)

2 (2–2)

–

2 (2–2)

–

 Holding for procedure^a

26 (46%)

14 (67%)

12 (33%)

0.03

 Active bleed

17 (30%)

8 (38%)

9 (25%)

0.30

 Recent TBI (≤48 h)

17 (30%)

12 (57%)

5 (14%)

< 0.01

 High bleeding risk

3 (5%)

0 (0%)

3 (8%)

0.30

 Low platelet count (< 50,000)

3 (5%)

1 (5%)

2 (6%)

0.90

 Epidural catheter

2 (4%)

2 (10%)

0 (0%)

0.13

 Intracranial pressure monitor

1 (2%)

1 (5%)

0 (0%)

0.37

 Other^b

13 (29%)

4 (19%)

9 (25%)

0.75

No documented reason for treatment holding or interruption

9 (16%)

0 (0%)

9 (25%)

0.01